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SUPPLEMENTARY NOTES
ABSTRACT
The PCRP Prostate Cancer Training Award has supported my training for the past 12 months. During this time, I have continued to work towards attaining a better understanding of (a) the biology of prostate cancer, (b) the biology of the Wnt/beta-catenin signaling pathway, (c) the principle and application of cutting edge techniques in modern molecular and cellular biology, and (d) the principle and application of genetically engineered mouse (GEM) models, with the intent of becoming uniquely positioned to investigate the role of Wnt/beta-catenin signaling in the initiation, progression and metastasis of spontaneous autochthonous prostate cancer and the emergence of the androgen depletion independent phenotype. In addition to this rigorous technical training, I have continued to attend weekly lab meetings, division wide Cancer Biology Seminar series, and the Pacific Northwest SPORE in Prostate Cancer meetings. In addition, I attended the PCRP's Innovative Minds in Prostate Cancer Today (IMPaCT) meeting in Atlanta, Georgia. Figure 1C ). In preparation for microinjection into FVB zygotes, PB/Wnt3-IRES-Luc was digested with NotI/XhoI and a 4829 bp fragment containing the transgene was gel purified. We have generated 2 independent lines and analyzed them for reporter gene expression (Luciferase) using the Xenogen IVIS system (Figure 2 ). While the expression of Luciferase was observed in the prostate of these animals, it was not spatially restricted to this organ.
SUBJECT TERMS
To provide better spatially restricted expression from the Probasin promoter, we reengineered our transgene construct to include 2 tandem repeats of the chicken β-globin HS4 region that functions as an insulator. This modified transgene was used for transgenesis in FVB zygotes. We observed a nearly identical pattern of Luciferase reporter expression in multiple founders with the modified transgene (data not shown). Figure 3 . Three copies of a strong transcriptional stop signal, flanked by lox p sites, will be inserted between the constitutively active CAG promoter (a combination of the chicken beta-actin promoter and cytomegalovirus immediateearly enhancer) and the downstream Wnt3/Luciferase bicistronic transgene. The entire transgene will be "knocked-in" to the ROSA locus via homologous recombination in mouse ES cells. The resulting "knock-in" mice will be crossed to ARR 2 PB-Cre mice in which expression of Cre recombinase is under control of the modified Probasin promoter. Bigenic (CAG/Wnt3-Luciferase; ARR 2 PB/Cre) mice will have the transcriptional stop signal deleted in the prostate epithelium and Wnt3/Luiferase expression should be restricted to epithelial cells of the mouse prostate.
Specific aim 2: Determine the influence of enforced Wnt3 expression during tumor progression and metastasis in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
We are waiting to select the CAG/loxSTOPlox/Wnt3-IRES-Luc transgenic line with the highest spatially restricted expression of Wnt3 prior to crossing to TRAMP.
Specific aim 3: Develop lines of reporter mice to detect activation of the Wnt/β-catenin pathway in vivo during normal development and cancer progression. We obtained the plasmid, 16xSuperTopFlash (16xSTF), from the Moon lab (University of Washington) and re-engineered the plasmid to contain a loxp-STOPx3-loxp cassette positioned upstream of the Luciferase ORF (Figure 4 ). Tissue specificity for the reporter transgene will be obtained by crossing the Wnt reporter mice to transgenic mice with Cre recombinase driven by tissue specific promoter, (eg. ARR 2 PB/Cre). We plan to test the reporter construct in a cell culture system by transfecting 293HEK cells with our modified reporter construct, pcDNA3.1/Cre, and pcDNA3.1/Wnt3 followed by a Luciferase assay to measure activation of the reporter. The plasmid will be digested with KpnI/SalI, a 4345 bp fragment will be gel purified and prepared for microinjection.
Key Research Accomplishments: none
Reportable Outcomes: none 
Conclusions:
The results of this work should support or refute the hypothesis that enforced expression of W n t 3 is sufficient to drive tumorigenesis in the mouse prostate and may provide support for Wnt3 in metastatic disease. A quantitative increase in the GU weight of bigenic (CAG/loxSTOPlox/Wnt3-IRES-Luc x TRAMP) animals compared to TRAMP mice would support the central hypothesis that deregulated Wnt signaling can promote prostate cancer in the mouse. Furthermore, an increase in the frequency or size of osteoblastic bone metastases in bigenic mice compared to age matched TRAMP mice would support the hypothesis that activated Wnt signaling in tumor cells can promote the formation of bone metastases.
We continue to generate CAG/loxSTOPlox/Wnt3-IRES-Luc knock-in mice. Founder animals will be imaged at 12, 18, and 24 weeks using a Xenogen IVIS to detect Luciferase expression.
Prostates from transgenic mice will be analyzed for cell proliferation, apoptosis, changes in morphology and pathology. The best expressing lines will be crossed to TRAMP mice.
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